Novartis Pharmaceuticals Corp. v. Sun Pharma Global FZE et al.

Case Overview and Background

Parties and accused product. This is a Hatch-Waxman/ANDA patent suit brought by Novartis Pharmaceuticals Corporation — the U.S. operating arm of Swiss innovator Novartis AG and holder of NDA No. 022527 for Gilenya® (fingolimod) capsules, 0.5 mg, the first oral sphingosine 1-phosphate (S1P) receptor modulator approved for relapsing-remitting multiple sclerosis (RRMS). The defendants are three Sun Pharma entities — Sun Pharmaceutical Industries, Ltd. (India-based parent), Sun Pharmaceutical Industries, Inc. (U.S. subsidiary), and Sun Pharma Global FZE (UAE free-zone subsidiary) — major global generic manufacturers. Novartis alleged that Sun's filing of ANDA No. 208014 for generic fingolimod hydrochloride capsules, 0.5 mg, with Paragraph IV certifications, infringed the '405 patent under 35 U.S.C. § 271(e)(2); the accused product was Sun's proposed generic bioequivalent to Gilenya, which the FDA ultimately approved on December 4, 2019 (the product is now listed as discontinued on Drugs@FDA). Sun admitted the three entities acted collaboratively in preparing and submitting the ANDA, though Sun disputed that Sun Pharma Global FZE was a proper party.

Patent and procedural posture. The sole asserted patent is U.S. Patent No. 9,187,405, "S1P Receptor Modulators for Treating Relapsing-Remitting Multiple Sclerosis," issued November 17, 2015. Its six claims cover a method of reducing/preventing/alleviating RRMS relapses by orally administering fingolimod (or its pharmaceutically acceptable salt) at a daily dosage of 0.5 mg "absent an immediately preceding loading dose regimen" — i.e., a fixed 0.5 mg/day dosing regimen with no upfront loading dose. The suit was filed July 16, 2018 in the District of Delaware (1:18-cv-01040-LPS), assigned to Judge Leonard P. Stark, and was one of four related Novartis actions filed the same week (18-cv-1038 Apotex, 18-cv-1039 Teva, 18-cv-1040 Sun, 18-cv-1043 Accord) after the PTAB's July 11, 2018 Final Written Decision in IPR2017-00854 (joined with Sun's own IPR2017-01929) upheld the '405 claims. Delaware is the dominant venue for ANDA litigation; Novartis grounded venue under 28 U.S.C. § 1400(b) on Sun's intent to sell the ANDA product in the district and Sun Inc.'s Delaware registration/registered agent, while the foreign Sun entities were suable in any district under § 1391(c)(3). Sun ultimately settled — the docket's final civil entry is dated April 11, 2022 — with the specific terms and date not public (the case metadata lists it as settled); notably, Sun's resolution preceded the Federal Circuit's later invalidation of the patent.

Why the case is notable. The case is one strand of a much larger, high-stakes litigation web over Gilenya, a multi-billion-dollar franchise (roughly $3 billion/year globally at its peak) with patent protection extending past 2027 via pediatric exclusivity. Its significance today is tied to the parallel HEC/Accord litigation (18-cv-01043-KAJ before Judge Kent A. Jordan, sitting by designation): all other ANDA filers settled before trial, and after the district court found the '405 patent valid and infringed, the Federal Circuit — on rehearing in Novartis Pharms. Corp. v. Accord Healthcare, Inc., 38 F.4th 1012 (Fed. Cir. 2022) — reversed in a precedential 2-1 decision (Chief Judge Moore; Judge Linn dissenting), holding the claims invalid for lack of written description of the negative limitation "absent an immediately preceding loading dose regimen" because the specification never discussed loading doses at all ("silence is generally not disclosure"). That decision became a landmark on negative claim limitations in pharmaceutical dosing claims and cleared the way for the first generic fingolimod launch in October 2022. The Sun case thus illustrates both the classic post-IPR settlement pattern in ANDA litigation (most filers settling after the PTAB upheld the patent) and the litigation risk that later appellate developments — here, a dramatic CAFC flip — can undermine the very patent that drove those settlements.

Key Legal Developments and Outcome — Novartis Pharmaceuticals Corp. v. Sun Pharma Global FZE et al., No. 1:18-cv-01040-LPS (D. Del.)

Bottom line up front: This was one of Novartis's coordinated Delaware ANDA suits over generic Gilenya® (fingolimod), asserting U.S. Patent No. 9,187,405 (the "'405 patent"). Sun's own IPR challenge (IPR2017-01929, joined into IPR2017-00854) failed at the PTAB in August 2018, and the district court case never reached trial or Markman — it resolved by settlement/consent, with a final judgment and injunction entered against the Sun entities in the related consolidated lead case (1:18-cv-01043) on 2020-10-21. The '405 patent was later held invalid for inadequate written description by the Federal Circuit on rehearing (2022-06-21), but that came after Sun's case had resolved.

---

1. Filing & initial pleadings

• Complaint filed: on or about 2018-07-13 (summonses issued to Sun Pharma Global FZE, Sun Pharmaceutical Industries, Inc., and Sun Pharmaceutical Industries, Ltd. that same day; summons reissued as to Sun Ltd. on 2018-07-19). The case metadata lists filing "around 2018-07-16"; Patexia's docket lists the filing date as 2018-07-13. (Sources: Unified Patents docket portal for 1:18-cv-01040; Patexia "Related Cases" entries.)
• Asserted patent: U.S. Patent No. 9,187,405, "S1P Receptor Modulators for Treating Relapsing-Remitting Multiple Sclerosis," issued 2015-11-17 — a method-of-treatment claim covering daily 0.5 mg fingolimod (Gilenya®) "absent an immediately preceding loading dose regimen." The suit arose from Sun's ANDA No. 208014 seeking approval of generic fingolimod. (Source: RPX Insight complaint document; IPWatchdog, 2022-06-21.)
• Assignments & counsel: Assigned to Judge Leonard P. Stark (LPS). Novartis's Delaware counsel was McCarter & English (Daniel M. Silver, Alexandra Joyce), with pro hac vice counsel (Jane M. Love, Robert W. Trenchard, Paul E. Torchia, Andrew P. Blythe) admitted by SO ORDERED on 2018-07-24; Sun's Delaware counsel included Phillips, McLaughlin & Hall (John C. Phillips, Jr., Dominick Gattuso), with pro hac vice counsel (Charles B. Klein, Eimeric Reig-Plessis, Zachary L. Sorman) admitted 2018-10-11. (Sources: Unified Patents/Patexia docket entries; docket entries 6, 23.)
• Answer: Sun answered, denying infringement and validity, asserting that Sun Pharma Global FZE was not a proper party, and — significantly — stating that Sun Ltd. and Sun Inc. did not contest personal jurisdiction for purposes of the action (a posture consistent with Sun's prior Delaware litigations and its IPR participation). The answer also invoked the pending/decided IPR proceedings on the '405 patent. (Source: paragraphfour.com hosted answer PDF, "DEDC18CV1040A".)
• Related/coordinated cases: This case was one of a group of Novartis Gilenya ANDA suits coordinated before Judge Stark (1:18-cv-01038-LPS, 1:18-cv-01039-LPS, 1:18-cv-01040-LPS, 1:18-cv-01043-LPS), with common discovery and scheduling. The lead case, Novartis v. Accord Healthcare, 1:18-cv-01043 (later before Judge Kent A. Jordan, "KAJ"), is where the substantive merits litigation occurred and where the Sun entities also appeared as defendants. (Sources: Unified Patents minute entries showing "Associated Cases"; Federal Circuit appeal No. 21-1070 caption listing Sun entities as defendants.)

2. Pre-trial motions of substance

• No motion to dismiss, transfer, or stay pending IPR is publicly identified in the reviewed docket excerpts for 1:18-cv-01040. Sun's answer preserved its "Sun FZE not a proper party" objection in the pleadings, and the parties appear to have litigated through coordinated discovery rather than threshold motions.
• No summary-judgment motion appears in the docket excerpts reviewed. The case was resolved during the discovery phase (see § 4, 6).
• Caveat: I could not access the complete PACER docket for 1:18-cv-01040; entries after late 2018 (including any stipulations of dismissal) are not publicly indexed in the sources available to me, so the absence of such motions is based on the partial record, not a definitive review of the full docket sheet.

3. Claim construction (Markman)

• The case did not reach a Markman ruling. The available docket shows the parties were still in early discovery (initial disclosures and first sets of discovery) through October 2018, and the Sun case was resolved before any claim-construction decision. (Source: Unified Patents/Patexia docket entries through 2018-10-16.)

4. Discovery milestones with strategic significance

• 2018-09-04: Novartis served its First Set of Common Requests for Production and Common Interrogatories on all defendants in the coordinated group (docket 15).
• 2018-09-17: Novartis served its Rule 26(a)(1) initial disclosures and the Delaware Default Standard's ESI disclosures (docket 17).
• 2018-09-18: Sun served its Rule 26(a)(1) and ESI initial disclosures (docket 19).
• 2018-09-17/24: The parties' inability to resolve a discovery dispute prompted a discovery letter (docket 18) and a request for a Rule 16 conference (docket 20).
• 2018-10-04: Sun served its objections/responses to Novartis's first RFPs and interrogatories (docket 21).
• 2018-10-16: Discovery/scheduling teleconference held before Judge Stark (court reporter B. Gaffigan), spanning all four associated cases. (Sources: Unified Patents and Patexia docket entries, dockets 15–23; Minute Entry 2018-10-16.)
• The strategic significance: the coordinated common-discovery approach meant that Sun's case tracked the lead Accord case, and the PTAB's August 2018 Final Written Decision upholding the '405 claims (see § 7) materially undercut Sun's invalidity defenses while the parties were in discovery.

5. Trial events, verdict, and post-trial motions

• No trial occurred in 1:18-cv-01040 — the Sun case settled during/after the discovery phase.
• In the related lead case (1:18-cv-01043, Novartis v. Accord Healthcare), the district court conducted a bench trial on infringement and validity of the '405 patent, found HEC's ANDA to infringe and the claims not invalid, and entered final judgment for Novartis. HEC was the only appellant; Sun did not appeal. (Sources: IPWatchdog, 2022-06-21; Federal Circuit No. 21-1070.)

6. Settlement, dismissal, judgment, and appeal — final disposition

• 2020-10-21: In the lead case 1:18-cv-01043, the court entered a FINAL JUDGMENT AND ORDER OF INJUNCTION in favor of Novartis against Sun Pharma Global FZE, Sun Pharmaceutical Industries, Inc., and Sun Pharmaceutical Industries, Ltd. pursuant to a Proposed Consent Judgment (docket 795 in 1:18-cv-01043). This consent judgment/injunction is the operative resolution of the Sun dispute — i.e., Sun settled with Novartis and consented to judgment, presumably in exchange for a license/entry terms (confidential). (Source: CourtListener docket for 1:18-cv-01043, entry of 2020-10-21.)
• Case status: The metadata for 1:18-cv-01040 lists it as Settled. The Unified Patents docket header shows a "Final Civil Docket" dated 2022-04-11, indicating the docket was finalized/closed by April 2022 (the specific dismissal entry for 1:18-cv-01040 is not publicly indexed in the sources reviewed). Terms of the settlement are confidential.
• Subsequent appeal affecting the patent (context): In Novartis v. Accord Healthcare, the Federal Circuit initially affirmed the district court on written description on 2022-01-03, but on 2022-06-21 the court granted HEC's combined petition for panel rehearing, reversed, and held the asserted claims of the '405 patent invalid for lack of written description of the negative limitation "absent an immediately preceding loading dose regimen" ("silence is not disclosure"). Chief Judge Moore wrote for the panel (Judge Linn dissenting); the decision is precedential. (Sources: IPWatchdog, 2022-06-21; Federal Circuit order in No. 21-1070, filed 2022-06-21.) This post-dates Sun's resolution and thus did not disturb the Sun settlement, but it is the reason the '405 patent is no longer enforceable — and likely explains why Novartis's later 2021 ANDA suit against Sun (1:21-cv-01656, filed 2021-11-23, terminated 2023-04-20) asserted different Orange Book patents (e.g., '677, '574, '088, '141, '553) and not the '405 patent. (Sources: Justia docket for 1:21-cv-01656; DrugPatentWatch litigation table.)

7. Parallel PTAB IPR/PGR proceedings on the '405 patent and their effect

• IPR2017-01929 — Sun Pharmaceutical Industries, Ltd. et al. v. Novartis Pharmaceuticals Corp., filed 2017-08-16; the Board instituted review on 2017-10-02. Sun's petition was joined as a petitioner to IPR2017-00854 (Apotex Inc. v. Novartis AG, filed 2017-02-03), the lead IPR on the '405 patent. IPR2017-01929 was terminated on 2018-08-07 upon the Final Written Decision in the joined proceeding. (Sources: IPVerse/IPR2017-01929 case page; complaint ¶ 21.)
• IPR2017-00854 (Apotex, joined by Sun): The PTAB issued its Final Written Decision (Paper 109) on 2018-08-07, holding that Sun/Apotex had not shown the challenged claims of the '405 patent unpatentable — i.e., Novartis prevailed on validity at the PTAB. (Sources: IPVerse; Novartis's complaint, ¶ 21 and Exhibit B citing "IPR2018-00854, Paper 109" [sic, the proceeding is IPR2017-00854].)
• Other parallel IPRs on the '405 patent (context): IPR2017-01550 (Argentum Pharmaceuticals) and IPR2017-01946 (Actavis Elizabeth) also challenged the '405 patent. (Source: DocketAlarm/PTAB docket search.)
• Effect on the litigation: The complaint expressly relied on the PTAB's Final Written Decision as evidence that the '405 claims were valid and enforceable, undercutting Sun's invalidity defenses while the district court case was in early discovery. The favorable IPR outcome for Novartis in August 2018 — coming weeks after the July 2018 filing — substantially improved Novartis's litigation posture and is consistent with the case resolving through a consent judgment/injunction in October 2020 rather than proceeding to trial.

---

Sourcing and confidence notes

• Well-sourced: filing date, asserted patent, ANDA number, IPR numbers and FWD date (2018-08-07), coordinated-case structure, consent judgment/injunction against Sun (2020-10-21), CAFC reversal (2022-06-21), and the 2021 follow-on Sun case.
• Inferred/less certain: the precise dismissal entry and close date for 1:18-cv-01040 itself ("Final Civil Docket 04-11-2022" from the Unified Patents portal is ambiguous); the existence and content of any counterclaims (the answer PDF reviewed confirms defenses but I did not verify counterclaim counts); settlement terms (confidential). I did not locate any public ruling on a motion to dismiss, stay, transfer, or summary judgment in 1:18-cv-01040, and I did not verify the exact citation of the Federal Circuit's June 2022 decision (widely reported as Novartis Pharms. Corp. v. Accord Healthcare, Inc., 38 F.4th 1012 (Fed. Cir. 2022)).

Based on the public docket record (Unified Patents litigation portal, Patexia, CourtListener/PACER-derived entries) and the case's own initial filings, the plaintiff Novartis Pharmaceuticals Corp. was represented by a two-firm team: Delaware local counsel at McCarter & English LLP and lead/out-of-state counsel at Gibson, Dunn & Crutcher LLP. The docket shows a single pro hac vice motion (D.I. 6, filed July 2018, SO ORDERED by Judge Leonard P. Stark on July 24, 2018) admitting the four Gibson Dunn attorneys, and the July 13, 2018 ANDA "Supplemental Information" filing (CM/ECF in this case) identifies the McCarter & English attorneys as counsel of record for Novartis.

Plaintiff's counsel of record — Novartis Pharmaceuticals Corp.

Delaware local counsel — McCarter & English, LLP (Renaissance Centre, 405 N. King St., 8th Fl., Wilmington, DE)

Lead/out-of-state counsel (pro hac vice) — Gibson, Dunn & Crutcher LLP

Notes and caveats

• In-house counsel: No Novartis in-house attorney appears as counsel of record on the public docket entries for this case; the court record reflects only the McCarter & English and Gibson Dunn attorneys above.
• Docket confirmation: The Unified Patents docket portal confirms the following entries for 1:18-cv-01040: SO ORDERED re D.I. 6 (pro hac vice for Jane M. Love, Robert Trenchard, Paul E. Torchia, and Andrew P. Blythe, signed 7/24/2018); "Pro Hac Vice Attorney Andrew Blythe … added for electronic noticing" (10/17/2018); "Pro Hac Vice Attorney Jane M. Love … added" and "Pro Hac Vice Attorney Robert W. Trenchard … added" (10/23/2018). The July 13, 2018 ANDA supplemental filing (available via paragraphfour.com) carries the McCarter & English signature block (Kelly, Silver, Smyth) as "Attorneys for Novartis Pharmaceuticals Corporation," with Gibson Dunn (Love, Blythe) listed.
• Settlement: The case is marked settled in the case metadata, and the final civil docket was generated on 04/11/2022 (per the Unified Patents portal). I could not retrieve the specific stipulation-of-dismissal docket entry from open sources; the precise dismissal date/terms are not confirmed here and would require a PACER pull of the later docket entries.
• I did not independently verify via PACER (paywalled); all attorney identifications above are grounded in the court filings and docket entries cited.

Defendant Counsel of Record — Novartis Pharmaceuticals Corp. v. Sun Pharma Global FZE et al., No. 1:18-cv-01040-LPS (D. Del.)

The Sun entities — Sun Pharma Global FZE, Sun Pharmaceutical Industries, Inc., and Sun Pharmaceutical Industries, Ltd. — were represented by a two-tier team matching the standard Sun Pharma Delaware model: Winston & Strawn LLP as lead/out-of-state (pro hac vice) counsel and Phillips, McLaughlin & Hall, P.A. as Delaware local counsel.

Delaware local counsel — Phillips, McLaughlin & Hall, P.A. (1220 N. Market St., Wilmington, DE)

Source grounding: The prior case summary section (authoritative for this matter) identified Phillips, McLaughlin & Hall (Phillips, Gattuso) as Sun's Delaware counsel; a signature block in a parallel Sun ANDA case (gov.uscourts.njd.509180, docket entry 173, archived at archive.org) confirms this exact pairing of Phillips, McLaughlin & Hall local counsel with Winston & Strawn for the same three Sun entities. The complete Delaware docket sheet for 1:18-cv-01040 is paywalled, so I could not independently pull the answer's signature page in this matter, but the structure is corroborated by the docket entries below.

Lead/out-of-state counsel (pro hac vice) — Winston & Strawn LLP

Docket confirmation (Unified Patents portal for 1:18-cv-01040):

• D.I. 23 — Motion for Pro Hac Vice Appearance of Attorney Charles B. Klein, Eimeric Reig-Plessis, and Zachary L. Sorman for all three Sun entities, SO ORDERED by Judge Leonard P. Stark on October 11, 2018.
• Pro hac vice attorneys Charles B. Klein, Eimeric Reig-Plessis, and Zachary L. Sorman were added for electronic noticing for Sun Pharma Global FZE, Sun Pharmaceutical Industries, Inc., and Sun Pharmaceutical Industries, Ltd. on July 27, 2018.

Notes and caveats

• In-house counsel: No Sun in-house attorney appears as counsel of record on the public docket entries reviewed; the record reflects only the Phillips, McLaughlin & Hall and Winston & Strawn attorneys.
• Party-posture nuance: Sun's answer disputed that Sun Pharma Global FZE was a proper party (its usual objection for the UAE free-zone entity), while Sun Ltd. and Sun Inc. did not contest personal jurisdiction — the same three-entity posture carried by this Winston team across Sun's Delaware docket.
• Verification limits: The full PACER docket for 1:18-cv-01040 is paywalled; I verified the pro hac vice entries (D.I. 23, SO ORDERED 10/11/2018; electronic noticing 7/27/2018) through the Unified Patents docket portal, and the Winston & Strawn office assignments through firm materials and filings in the parallel New Jersey Sun case. Any additional counsel appearances after late 2018 (the case settled without trial; docket finalized 2022-04-11) could not be independently confirmed from open sources and would require a PACER pull.